Edition:
United States

Dicerna Pharmaceuticals Inc (DRNA.OQ)

DRNA.OQ on NASDAQ Stock Exchange Global Select Market

13.50USD
20 Nov 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$13.50
Open
$13.35
Day's High
$13.70
Day's Low
$13.02
Volume
135,410
Avg. Vol
187,448
52-wk High
$17.96
52-wk Low
$6.81

Latest Key Developments (Source: Significant Developments)

Dicerna Qtrly Loss Per Share $0.35
Monday, 5 Nov 2018 04:05pm EST 

Nov 5 (Reuters) - Dicerna Pharmaceuticals Inc ::DICERNA REPORTS THIRD QUARTER 2018 FINANCIAL AND OPERATING RESULTS AND PROVIDES CORPORATE UPDATE.DICERNA PHARMACEUTICALS INC - ON TRACK TO INITIATE REGISTRATION TRIAL IN Q1 2019 FOR DCR-PHXC IN PRIMARY HYPEROXALURIA.DICERNA PHARMACEUTICALS INC - AS OF SEPTEMBER 30, 2018, DICERNA HAD $180.4 MILLION IN CASH, CASH EQUIVALENTS AND HELD-TO-MATURITY INVESTMENTS.DICERNA PHARMACEUTICALS INC - QTRLY LOSS PER SHARE $0.35.DICERNA PHARMACEUTICALS INC - QTRLY REVENUE FROM COLLABORATIVE ARRANGEMENTS $1.5 MILLION.  Full Article

Alexion And Dicerna Announce Collaboration To Discover And Develop RNAi Therapies For Complement-Mediated Diseases
Wednesday, 24 Oct 2018 06:30am EDT 

Oct 24 (Reuters) - Alexion Pharmaceuticals Inc ::ALEXION AND DICERNA ANNOUNCE COLLABORATION TO DISCOVER AND DEVELOP RNAI THERAPIES FOR COMPLEMENT-MEDIATED DISEASES.DICERNA PHARMACEUTICALS INC - DICERNA TO RECEIVE UPFRONT PAYMENT OF $22 MILLION AND EQUITY INVESTMENT OF $15 MILLION.DICERNA PHARMACEUTICALS INC - DEAL HAS POTENTIAL FOR ADDITIONAL MILESTONE-DEPENDENT AND ROYALTY PAYMENTS.DICERNA PHARMACEUTICALS - ALEXION MAKING A CONCURRENT $15 MILLION EQUITY INVESTMENT IN DICERNA AT A PREMIUM TO MARKET AS OF COLLABORATION EFFECTIVE DATE..DICERNA - COLLABORATION ALSO PROVIDES FOR POTENTIAL ADDITIONAL DEVELOPMENT AND APPROVAL-RELATED MILESTONE PAYMENTS OF UP TO $105 MILLION PER TARGET.DICERNA PHARMACEUTICALS INC - COLLABORATION ALSO PROVIDES FOR SALES MILESTONES AND MID-SINGLE TO LOW-DOUBLE DIGIT ROYALTIES ON FUTURE PRODUCT SALES..  Full Article

Dicerna Pharmaceuticals Q1 Loss Per Share $0.30
Monday, 14 May 2018 04:05pm EDT 

May 14 (Reuters) - Dicerna Pharmaceuticals Inc ::DICERNA REPORTS FIRST QUARTER 2018 FINANCIAL AND OPERATING RESULTS AND PROVIDES CORPORATE UPDATE.DICERNA PHARMACEUTICALS INC - QTRLY LOSS PER SHARE $0.30.DICERNA PHARMACEUTICALS INC - BELIEVES THAT IT HAS SUFFICIENT CASH TO FUND EXECUTION OF ITS CURRENT CLINICAL AND OPERATING PLAN THROUGH 2019.DICERNA PHARMACEUTICALS INC - FOR THREE-MONTH PERIOD ENDED MARCH 31, 2018, DICERNA RECOGNIZED $1.5 MILLION OF REVENUE ASSOCIATED WITH BI AGREEMENT.  Full Article

Ecor1 Capital Llc Reports a 9.4 Percent Passive Stake In Dicerna Pharmaceuticals
Wednesday, 3 Jan 2018 06:09am EST 

Jan 3 (Reuters) - Dicerna Pharmaceuticals Inc ::ECOR1 CAPITAL, LLC REPORTS A 9.4 PERCENT PASSIVE STAKE IN DICERNA PHARMACEUTICALS AS OF DEC 20, 2017.  Full Article

RA Capital Management LLC Reports 9.9 Pct Stake In Dicerna Pharmaceuticals
Wednesday, 20 Dec 2017 05:50pm EST 

Dec 20 (Reuters) - Dicerna Pharmaceuticals Inc ::RA CAPITAL MANAGEMENT LLC REPORTS 9.9 PERCENT STAKE IN DICERNA PHARMACEUTICALS AS OF DEC 18 - SEC FILING.RA CAPITAL MANAGEMENT LLC PREVIOUSLY REPORTED 19.9 PERCENT STAKE IN DICERNA PHARMACEUTICALS AS OF DEC 13.RA CAPITAL MANAGEMENT -ON DEC 18,ALL DICERNA PHARMA SHARES OF REDEEMABLE CONVERTIBLE PREFERRED STOCK HELD BY RA CAPITAL WERE CONVERTED INTO COMMON STOCK.  Full Article

Bain Capital Life Sciences Fund Reports 15.7 Percent Stake In Dicerna Pharmaceuticals
Tuesday, 19 Dec 2017 04:51pm EST 

Dec 19 (Reuters) - Bain Capital Life Sciences Fund L.P::BAIN CAPITAL LIFE SCIENCES FUND L.P. REPORTS 15.7 PERCENT STAKE IN DICERNA PHARMACEUTICALS INC AS ON DEC 18 - SEC FILING.BAIN CAPITAL LIFE SCIENCES FUND L.P. HAD PREVIOUSLY REPORTED 26.4 PERCENT STAKE IN DICERNA PHARMACEUTICALS INC AS ON SEPT 15.BAIN CAPITAL LIFE SCIENCES-ON DEC 18,ALL DICERNA PHARMA SHARES OF REDEEMABLE CONVERTIBLE PREFERRED STOCK HELD BY BAIN WERE CONVERTED INTO COMMON STOCK.  Full Article

Dicerna Announces Pricing Of Follow-On Public Offering Of Common Stock
Thursday, 14 Dec 2017 09:29am EST 

Dec 14 (Reuters) - Dicerna Pharmaceuticals Inc ::DICERNA ANNOUNCES PRICING OF FOLLOW-ON PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 5.71 MILLION COMMON SHARES PRICED AT $7.00PER SHARE.  Full Article

Dicerna Pharmaceuticals Files Preliminary Prospectus Supplement Related To A Potential Common Stock Offering
Thursday, 14 Dec 2017 08:09am EST 

Dec 14 (Reuters) - Dicerna Pharmaceuticals Inc ::DICERNA PHARMACEUTICALS INC FILES PRELIMINARY PROSPECTUS SUPPLEMENT RELATED TO A POTENTIAL COMMON STOCK OFFERING - SEC FILING.  Full Article

Dicerna announces proposed public offering of common stock
Wednesday, 13 Dec 2017 04:45pm EST 

Dec 13 (Reuters) - Dicerna Pharmaceuticals Inc ::DICERNA ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.DICERNA PHARMACEUTICALS INC - TO USE PROCEEDS FROM OFFERING FOR PRECLINICAL STUDIES & CLINICAL TRIALS.  Full Article

Dicerna Announces First Human Dosed In Phase 1 Clinical Trial Of DCR-PHXC
Thursday, 7 Dec 2017 07:30am EST 

Dec 7 (Reuters) - Dicerna Pharmaceuticals Inc ::DICERNA ANNOUNCES FIRST HUMAN DOSED IN PHASE 1 CLINICAL TRIAL OF DCR-PHXC FOR TREATMENT OF ALL FORMS OF PRIMARY HYPEROXALURIA.DICERNA PHARMACEUTICALS - ANTICIPATES THAT HUMAN PROOF-OF-CONCEPT DATA FROM PHASE 1 TRIAL FOR DCR-PHXC WILL BE AVAILABLE IN SECOND HALF OF 2018.  Full Article

Photo

Eli Lilly makes bet on gene-silencing drug firm Dicerna

Eli Lilly and Co is spending $100 million for a stake in Dicerna Pharmaceuticals Inc as part of a licensing deal, making it the latest major drugmaker to bet on gene-silencing technology.